Piperacillin/tazobactam plus erythromycin improves clinical outcomes in AECOPD with bacterial lower respiratory tract infections: a retrospective cohort study
Abstract
It remains uncertain whether patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and bacterial lower respiratory tract infections (LRTIs) could similarly benefit from β-lactam and macrolide antibiotics therapy as community-acquired pneumonia (CAP) does. In this study, we compared the clinical success rates of piperacillin/tazobactam (TZP) monotherapy versus its combination with erythromycin lactobionate injection (Ery) in patients with AECOPD and bacterial LRTIs and developed a machine learning (ML) model to predict treatment outcomes. The patients with AECOPD and bacterial LRTIs received antimicrobial therapy with either piperacillin-tazobactam (TZP) alone or TZP in combination with Ery. Inverse probability of treatment weighting (IPTW) was performed between the two groups. Subsequently, a stacking ensemble learning (SEL) model was developed and deployed as a web application to simultaneously predict clinical outcomes for both treatment options. The result demonstrated that TZP combined with Ery significantly reduced the incidence of clinical treatment failure compared to TZP monotherapy (14.00% vs. 19.75%; OR, 0.66; 95% CI, 0.49–0.89; P = 0.006). In an independent test set, the SEL model demonstrated strong performance across multiple metrics, including ROC-AUC (0.71), recall (sensitivity) (0.72), and accuracy (0.69). Finally, a web application based on the SEL was developed ( http://106.12.146.54/ ). This study demonstrated that the…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
- Clinical challenges treatingStenotrophomonas maltophiliainfections: an update
- Guidelines on Implementing Antimicrobial Stewardship Programs in Korea
- Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies
- What’s old is new again: Insights into diabetic foot microbiome
- Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.